Active substance
Ketamine
- SFDA 4
- US FDA 12
- Health Canada 7
- US price lines 3
- NHS prices 2
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TEKAM 50MG-ML 10ML VIAL | 50 mg/ml | Injection · Intravenous use | 1 Vial | SAR 26.55 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Tekam | 10 mg/ml | Solution for injection/infusion · Intramuscular and intravenous use | 10 Vial | SAR 104.20 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Tekam | 50 mg/ml | Solution for injection/infusion · Intramuscular and intravenous use | 10 Vial | SAR 265.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| TEKAM 10MG-ML 10ML VIAL | 10 mg/ml | Injection · Intravenous use | 1 Vial | SAR 6.50 | NCE · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ANESTHESIA; ANXIETY DISORDERS; BIPOLAR II DISORDER; BURN MANAGEMENT; EPIDERMOLYSIS BULLOSA; POSTOPERATIVE PAIN
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| KETALAR | EQ 10MG BASE/ML; EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | PH HEALTH | Prescription | 19 Feb 1970 |
| KETAMINE HYDROCHLORIDE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | HIKMA PHARMS | Prescription | 22 Mar 1996 |
| KETAMINE HYDROCHLORIDE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | HOSPIRA | Prescription | 27 Jun 1996 |
| KETAMINE HYDROCHLORIDE | EQ 10MG BASE/ML; EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | EUGIA PHARMA | Prescription | 28 Dec 2001 |
| KETAMINE HYDROCHLORIDE | EQ 10MG BASE/ML; EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 13 Jan 2023 |
| KETAMINE HYDROCHLORIDE | EQ 10MG BASE/ML; EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | GLAND | Prescription | 24 Jan 2023 |
| KETAMINE HYDROCHLORIDE | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | solution · intramuscular, intravenous | BAXTER HLTHCARE CORP | Prescription | 17 Sep 2025 |
| KETAMINE HYDROCHLORIDE | EQ 10MG BASE/ML | injectable · injection | CAPLIN | Discontinued | 7 Aug 2025 |
| KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | solution · intramuscular, intravenous | BAXTER HLTHCARE CORP | Discontinued | 17 Sep 2025 |
| KETAMINE HCL | EQ 10MG BASE/ML | injectable · injection | QUAD PHARMS | Discontinued | |
| KETAMINE HCL | EQ 50MG BASE/ML | injectable · injection | QUAD PHARMS | Discontinued | |
| KETAMINE HCL | EQ 100MG BASE/ML | injectable · injection | QUAD PHARMS | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| KETALAR | 00224391 | 10 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SEARCHLIGHT PHARMA INC |
| KETALAR | 00224405 | 50 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SEARCHLIGHT PHARMA INC |
| KETAMINE HYDROCHLORIDE INJECTION USP | 02246795 | 10 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| KETAMINE HYDROCHLORIDE INJECTION USP | 02246796 | 50 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| KETAMINE HYDROCHLORIDE INJECTION, USP | 02550431 | 10 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| KETAMINE HYDROCHLORIDE INJECTION, USP | 02550458 | 50 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| KETAMINE INJECTION, BP | 02535645 | 50 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | KETALAR 500 MG/10 ML VIAL | $0.67242 | per ML | 23 Sep 2026 |
| US NADAC | KETAMINE 500 MG/10 ML VIAL | $0.5563 | per ML | 23 Sep 2026 |
| US NADAC | KETAMINE 500 MG/5 ML VIAL | $1.78037 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Ketamine 200mg/20ml solution for injection vials | £5.06 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Ketamine 500mg/10ml solution for injection vials | £8.77 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 1.1.2. General anaesthetics and oxygen > Injectable medicines · core
Anaesthetics and therapeutic gases
Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride) (EMLc); 50 mg per mL in vial (as hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 23 Mar 2026 KETALAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.